Fisetin Side Effects: What Studies Report

What the literature actually contains on fisetin safety

Fisetin (3,7,3',4'-tetrahydroxyflavone) is a plant flavonol that has been investigated mainly as a senolytic — a compound studied for its capacity to eliminate senescent cells. Anyone looking for a tidy adverse-event table will find that the published record does not yet provide one. A 2024 review of fisetin as a senotherapeutic agent summarised the preclinical evidence across age-related diseases and set out the translational questions that remained unresolved, including how findings in cells and rodents relate to human outcomes (PMID 39384074). A 2025 review of senolytics and senomorphics grouped fisetin with other candidate agents for healthy aging and discussed the advances and open challenges facing the field as a whole (PMID 40994903).

This page is for educational purposes only and is not medical advice; consult a licensed physician about any health decision, medication, supplement or research compound. Nothing here describes a protocol, and no quantities are presented, because the verified literature summarised below does not support presenting them outside the context of the original papers.

Human Data: What Studies Report

Human evidence on fisetin is sparse. A 2024 pilot study examined the effects of fisetin on measures of biological aging, and the researchers described the work explicitly as a pilot investigation rather than a definitive controlled trial (PMID 39269340). Pilot designs of this type are generally too small to characterise uncommon adverse events, and that limitation is structural rather than a criticism of any one paper: a study enrolling a handful of participants can only detect side effects that occur frequently.

The closest thing to a formal first-in-human safety package in the verified literature concerns a derivative rather than the parent molecule. A 2025 phase 1 report in healthy adult volunteers assessed the safety, pharmacokinetics and cardiodynamics of CMS121, described as a novel small-molecule fisetin derivative with neuroprotective properties (PMID 40093210). That distinction matters for interpretation. A derivative is engineered to change absorption, metabolism or potency, so its tolerability profile cannot be assumed to transfer to fisetin, and fisetin's profile cannot be inferred from it either. The inclusion of cardiodynamic assessment in the study design also illustrates what regulators and trialists typically want from a new small molecule: structured cardiac monitoring alongside pharmacokinetics.

Why "no reported side effects" is not the same as "no side effects"

Across the reviews, fisetin is repeatedly described as a candidate under investigation rather than an agent with an established human safety record (PMID 39384074). When a compound has been studied mostly in cell culture and animal models, the absence of published adverse events reflects the absence of large, long, systematically monitored human trials — not a demonstration of safety. The 2025 senolytics review framed translation to human healthy-aging use as an unfinished project for the class (PMID 40994903).

Animal and Laboratory Toxicology: What Studies Report

One of the more directly safety-focused papers in the verified set did not test free fisetin. A 2023 study assessed the toxicity and genotoxic safety profile of a novel fisetin ruthenium-p-cymene complex in mice (PMID 37008693). Metal-coordinated complexes are separate chemical entities with their own distribution and elimination behaviour, so the study speaks to that complex rather than to dietary or supplemental fisetin. Its value for readers is methodological: it shows the type of work — general toxicity plus genotoxicity endpoints in an animal model — that constitutes a conventional preclinical safety assessment.

Laboratory work has also examined how cells respond to fisetin delivered from a material rather than systemically. A 2022 study reported an osteogenic effect of fisetin doping in bioactive glass/poly(caprolactone) hybrid scaffolds (PMID 35811886). In vitro scaffold studies typically pair functional outcomes with cell-viability checks, and the concentrations reaching cells in such systems are determined by release from the material — a context that does not map onto oral exposure in a person.

Cardiovascular and Blood-Pressure Signals: What Studies Report

The most concrete pharmacological signal with plausible tolerability implications is haemodynamic. A 2026 study reported comprehensive vasodilatory and antihypertensive effects of fisetin using both ex vivo vessel preparations and in vivo models (PMID 42341591). Researchers investigating a blood-pressure-lowering compound generally note that the same mechanism responsible for a therapeutic effect in hypertension can, in other contexts, produce unwanted lowering of blood pressure; the cited work characterised the vasodilatory effect itself rather than adverse events in people.

A second cardiovascular thread is protective rather than adverse in the model studied. A 2023 study reported that fisetin attenuated doxorubicin-induced cardiotoxicity by inhibiting the insulin-like growth factor II receptor apoptotic pathway through estrogen receptor-α/-β activation (PMID 37186468). Two observations follow from that report. First, interaction with an oncology drug — even a beneficial interaction in an animal model — demonstrates that fisetin is not pharmacologically inert in the presence of other agents. Second, the mechanism the study identified runs through estrogen receptors.

Receptor Activity and Genotoxicity Questions: What Studies Report

Because the cardioprotection study attributed fisetin's effect to estrogen receptor-α and -β activation (PMID 37186468), fisetin sits near the broader literature on plant compounds with estrogen-receptor activity. A 2005 review of the genotoxicity of phytoestrogens summarised laboratory evidence that dietary plant compounds in this category have produced genotoxic effects in test systems, and discussed how such findings should be weighed (PMID 15914213). That review is a class-level discussion rather than a fisetin-specific toxicology report, and the distinction between in vitro genotoxicity assays and in vivo outcomes was part of what it addressed. It is cited here to show why genotoxicity endpoints appear in modern fisetin-related safety work, such as the mouse study of the ruthenium complex (PMID 37008693).

Absorption, Microbiota and Between-Person Variability: What Studies Report

Tolerability depends partly on how much of a compound is absorbed and what happens to it first. A 2024 review examined the interaction between nutraceuticals and gut microbiota as a therapeutic approach in Parkinson's disease, describing a bidirectional relationship in which microbial communities modify ingested plant compounds while those compounds in turn alter the microbiota (PMID 38587699). Researchers in that review treated flavonoid-class nutraceuticals as substrates and modulators of the gut environment. For interpreting safety literature, the practical implication is that exposure after oral intake is not fixed across individuals, which complicates comparisons between studies.

Senolytic Context: Why Class-Level Questions Dominate

Much of the safety discussion around fisetin is really a discussion about senolytics. Clearing senescent cells is an intervention on a cell population that has both harmful and useful roles, and reviews of the class have framed selectivity as a central concern (PMID 40994903). The 2024 senotherapeutic review likewise described fisetin's promise in age-related disease models alongside unresolved translational issues (PMID 39384074).

Oncology work illustrates how deliberately senescent-cell targeting is now being pursued. A 2026 study reported that targeting senescent EGR1-positive B cells enhanced immunotherapy efficacy in esophageal squamous cell carcinoma models (PMID 41483805). That report concerns a specific senescent immune-cell population in a cancer setting; it is included here only to show that senescent-cell clearance is an active pharmacological strategy with immune consequences, which is why class-level safety questions are not hypothetical.

A useful contrast is metformin. A 2019 review of metformin and aging synthesised evidence for it as a candidate geroprotector drawing on its extensive clinical use in diabetes (PMID 31522175). Compounds with decades of prescribing history arrive at aging research with an inherited adverse-event record; fisetin does not, and that asymmetry explains why reviews describe its human tolerability as under-characterised (PMID 39384074).

Evidence Map by Domain

Limitations Readers Should Keep in View

• Different chemical entities. Two of the most safety-oriented papers tested a derivative (PMID 40093210) and a metal complex (PMID 37008693), not fisetin as consumed in foods or supplements.
• Model-to-human gaps. Vasodilation and cardioprotection were characterised in vessel preparations and animal models (PMID 42341591, PMID 37186468), and reviews have emphasised that translation remains incomplete (PMID 39384074).
• Study size. The available human fisetin work was pilot-scale (PMID 39269340).
• Variable exposure. Gut-microbiota interactions can alter what reaches circulation from ingested plant compounds (PMID 38587699).

How This Page Differs From the Fisetin Course

This page catalogues what published studies reported about safety, toxicology and tolerability signals. The PeptideU fisetin learning course covers the compound's biology, senolytic mechanism and study landscape in teaching form, with reading order and background rather than an adverse-event survey. Readers interested in why fisetin is studied at all — rather than what safety endpoints have been measured — will find that material more useful.

References

• Fisetin as a senotherapeutic agent: Evidence and perspectives for age-related diseases (Mechanisms of Ageing and Development, 2024)
• Targeting Cellular Senescence for Healthy Aging: Advances in Senolytics and Senomorphics (Drug Design, Development and Therapy, 2025)
• The Effects of Fisetin on Reducing Biological Aging: A Pilot Study (Alternative Therapies in Health and Medicine, 2024)
• Safety, Pharmacokinetics, and Cardiodynamics of CMS121, a Novel Small Molecule Fisetin Derivative with Neuroprotective Properties, in Phase 1 Healthy Adult Volunteers (medRxiv, 2025)
• Assessment of toxicity and genotoxic safety profile of novel fisetin ruthenium-p-cymene complex in mice (Toxicological Research, 2023)
• Comprehensive vasodilatory and antihypertensive effects of 3,7,3',4'-tetrahydroxyflavone (fisetin): Ex vivo and in vivo evidence (Biomedicine & Pharmacotherapy, 2026)
• Fisetin attenuates doxorubicin-induced cardiotoxicity by inhibiting the insulin-like growth factor II receptor apoptotic pathway through estrogen receptor-α/-β activation (Phytotherapy Research, 2023)
• Genotoxicity of phytoestrogens (Mutation Research, 2005)
• Osteogenic Effect of Fisetin Doping in Bioactive Glass/Poly(caprolactone) Hybrid Scaffolds (ACS Omega, 2022)
• The Interaction Between Nutraceuticals and Gut Microbiota: a Novel Therapeutic Approach to Prevent and Treatment Parkinson's Disease (Molecular Neurobiology, 2024)
• Targeting senescent EGR1(+) B cells enhances immunotherapy efficacy in esophageal squamous cell carcinoma (Cell Reports Medicine, 2026)
• Metformin and Aging: A Review (Gerontology, 2019)